303-50-4

Basic information

• Product Name: NORCYCLOBENZAPRINE
• Synonyms: NORCYCLOBENZAPRINE;3-(5H-Dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine
• CAS NO: 303-50-4
• Molecular Formula: C19H19N
• Molecular Weight: 261.36086
• Mol File: 303-50-4.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 412.3°Cat760mmHg
• Flash Point: 204.4°C
• Appearance: /
• Density: 1.106g/cm³
• Vapor Pressure: 5.24E-07mmHg at 25°C
• Refractive Index: 1.652
• Solubility: Chloroform
• PKA: 9.97±0.10(Predicted)
• CAS DataBase Reference: NORCYCLOBENZAPRINE(CAS DataBase Reference)
• NIST Chemistry Reference: NORCYCLOBENZAPRINE(303-50-4)
• EPA Substance Registry System: NORCYCLOBENZAPRINE(303-50-4)

Safety Data

• Hazardous Substances Data: 303-50-4(Hazardous Substances Data)

Usage

Uses

Norcyclobenzaprine is an intermediate in the synthesis of Cyclobenzaprine N-β-D-Glucuronide (C987755). Cyclobenzaprine N-β-D-Glucuronide is a metabolite of Cyclobenzaprine.

InChI:InChI=1/C19H19N/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19/h2-5,7-13,20H,6,14H2,1H3

Upstream product

• 16234-95-0 ethyl N-<3-(5H-dibenzocyclohepten-5-ylidene)propyl>-N-methylcarbamate 
• 303-53-7 Cyclobenzaprine 
• 2222-33-5 dibenzosuberenon 
• 1971-54-6 5-ethyl-5-hydroxy-5H-dibenzo[a,d]cycloheptene 
• 1614-62-6 5-(2'-bromoethylidene)-5H-dibenzo[a,d]cycloheptene 
• 1614-61-5 5-(2-cyanoethylidene)-5H-dibenzo[a,d]cycloheptene 
• 1614-63-7 5-ETHYLIDENE-5H-DIBENZO[a,d]CYCLOHEPTENE 
• 1614-47-7 5-(3-aminopropylidene)-5H-dibenzo[a,d]cycloheptene 
• 74-88-4 methyl iodide 
• 14471-62-6 5-(3-bromo-1-propylidene)-5H-dibenzo[a,d]cycloheptene 
• 74-89-5 methylamine 

Downstream Products

• 16234-95-0 ethyl N-<3-(5H-dibenzocyclohepten-5-ylidene)propyl>-N-methylcarbamate 

Relevant articles and documents

Development of tricyclic N-benzyl-4-hydroxybutanamide derivatives as inhibitors of GABA transporters mGAT1-4 with anticonvulsant, antinociceptive, and antidepressant activity

γ-Aminobutyric acid (GABA) neurotransmission has a significant impact on the proper functioning of the central nervous system. Numerous studies have indicated that inhibitors of the GABA transporters mGAT1-4 offer a promising strategy for the treatment of several neurological disorders, including epilepsy, neuropathic pain, and depression. Following our previous results, herein, we report the synthesis, biological evaluation, and structure-activity relationship studies supported by molecular docking and molecular dynamics of a new series of N-benzyl-4-hydroxybutanamide derivatives regarding their inhibitory potency toward mGAT1-4. This study allowed us to identify compound 23a (N-benzyl-4-hydroxybutanamide bearing a dibenzocycloheptatriene moiety), a nonselective GAT inhibitor with a slight preference toward mGAT4 (pIC50 = 5.02 ± 0.11), and compound 24e (4-hydroxy-N-[(4-methylphenyl)-methyl]butanamide bearing a dibenzocycloheptadiene moiety) with relatively high inhibitory activity toward mGAT2 (pIC50 = 5.34 ± 0.09). In a set of in vivo experiments, compound 24e successively showed predominant anticonvulsant activity and antinociception in the formalin model of tonic pain. In contrast, compound 23a showed significant antidepressant-like properties in mice. These results were consistent with the available literature data, which indicates that, apart from seizure control, GABAergic neurotransmission is also involved in the pathophysiology of several psychiatric diseases, however alternative mechanisms underlying this action cannot be excluded. Finally, it is worth noting that the selected compounds showed unimpaired locomotor skills that have been indicated to give reliable results in behavioral assays.

NOVEL DIARYLALKENE DERIVATIVES AND NOVEL DIARYLALKANE DERIVATIVES

The invention relates to a compound represented by the following general formula (1) or its analogue, which selectively inhibit N-type calcium channels or its analogue, and to a method for treating pain etc. comprising the compound represented by the following general formula (1) or its analogue to a patient in need of such treatment: wherein, A represents CH=CH, etc., a, b, c and d represents CH etc., R1, R2, R3, R4, R5 and R6 represents H etc., V--W represents C=C, etc., n represents 0 to 3, Y1 represents O etc., B represents--(CH2)vCHR21 wherein v is 0 to 3, R21 represents H, a lower alkyl group or the like, etc., G represents--CO--, a covalent bond, etc., m is 0 to 6, R7 and R8 represents H, a lower alkyl group,--COR18a,--COOR20 wherein R18a and R20 each represents a lower alkyl group or the like, etc.

Tricyclic compounds and method for treating allergic diseases

Tricyclic compounds represented by the following formula: STR1 wherein X represents --CH=CH--, --CH2 O--, or --O--; R1 represents a lower alkyl group, R2 represents a hydrogen atom or a lower alkyl group; and n represents an integer of from 1 to 5, pharmacologically acceptable salts thereof, and a method for preparing the same. The present compounds have anti-allergic and anti-histaminic activities and reduced side effects, and are useful as anti-allergic agents and anti-histaminic agents.